Product Center
The Launch Meeting of the Phase III Clinical Trial of the Quadrivalent Influenza Virus Subunit Vaccine (Ages 6–35 Months) Was Successfully Completed
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-02-04
- Views:
(Summary description)As the old year concludes with splendid achievements, the new year begins with renewed progress! On January 31st, the kick-off meeting for the Phase III clinical trial of Ab&B Bio-Tech Co., Ltd. JS’s quadrivalent influenza virus subunit vaccine (ages 6–35 months) was held at the Henan clinical research site. This marks another Phase III clinical trial following the successful completion of the quadrivalent influenza virus subunit vaccine (ages 3 and above) Phase III trial.
The Launch Meeting of the Phase III Clinical Trial of the Quadrivalent Influenza Virus Subunit Vaccine (Ages 6–35 Months) Was Successfully Completed
(Summary description)As the old year concludes with splendid achievements, the new year begins with renewed progress! On January 31st, the kick-off meeting for the Phase III clinical trial of Ab&B Bio-Tech Co., Ltd. JS’s quadrivalent influenza virus subunit vaccine (ages 6–35 months) was held at the Henan clinical research site. This marks another Phase III clinical trial following the successful completion of the quadrivalent influenza virus subunit vaccine (ages 3 and above) Phase III trial.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-02-04 16:17
- Views:
As the old year concludes with splendid achievements, the new year begins with renewed progress! On January 31st, the kick-off meeting for the Phase III clinical trial of Ab&B Bio-Tech Co., Ltd. JS’s quadrivalent influenza virus subunit vaccine (ages 6–35 months) was held at the Henan clinical research site. This marks another Phase III clinical trial following the successful completion of the quadrivalent influenza virus subunit vaccine (ages 3 and above) Phase III trial.
This clinical trial is a randomized, blinded, active-controlled Phase III study to evaluate the safety and immunogenicity of the quadrivalent influenza virus subunit vaccine in healthy participants aged 6–35 months. The objective is to verify the efficacy and safety of the vaccine in this pediatric population.Relevant information
-
The Launch Meeting of Phase I/II Clinical Trial for Recombinant Herpes Zoster Vaccine (CHO Cell) was successfully heldRecently, the Phase I/II clinical trial launch meeting for the recombinant herpes zoster vaccine (CHO cell), co-developed by Ab&B Bio-Tech CO., LTD. JS. and Yither Biotech (Shanghai) Co., Ltd., was successfully held in Henan, and the first-in-human (FIH) dosing was successfully completed. - Ab&B Bio and Yither Bio Have Both Obtained Qualification Certification! 12-30
- Kickoff Meeting for Clinical Research on Quadrivalent Influenza Virus Subunit Vaccine in Children with Nephrotic Syndrome Successfully Held 12-25
- IND Application for Influenza Virus Subunit Vaccine (Adjuvanted) Approved 10-30
- The Application for the Marketing of Trivalent Influenza Virus Subunit Vaccine has been Accepted! 10-08
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
